Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

26.00
+0.95003.79%
Post-market: 26.000.00000.00%16:54 EST
Volume:1.19M
Turnover:30.70M
Market Cap:3.26B
PE:-16.28
High:26.15
Open:25.21
Low:24.75
Close:25.05
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines

Reuters
·
28 Feb

Stock Track | Apellis Pharmaceuticals Plummets 5.31% Despite Better-Than-Expected Q4 Earnings

Stock Track
·
28 Feb

Apellis Pharmaceuticals Shares Reverse Course From Premarket Gains; Last Down 4.4%

THOMSON REUTERS
·
28 Feb

Apellis Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

Zacks
·
28 Feb

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Upcoming Economic Data

MT Newswires Live
·
28 Feb

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
28 Feb

BUZZ-Apellis rises after quarterly revenue beats estimates

Reuters
·
28 Feb

Apellis Pharmaceuticals Shares up 6.8% Premarket After Q4 Results

THOMSON REUTERS
·
28 Feb

Apellis Pharmaceuticals Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
28 Feb

Apellis Pharmaceuticals' Cash And Cash Equivalents Of $411.3M As Of December 31, 2024; Projected Revenues And Cash Expected To Be Sufficient To Fund Operations To Profitability

Benzinga
·
28 Feb

Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 Net Loss $-0.29 a Share, vs. FactSet Est of $-0.37 Loss

MT Newswires Live
·
28 Feb

Stock Track | Apellis Pharmaceuticals Soars 9.62% Pre-Market on Revenue Growth Despite Q4 Loss

Stock Track
·
28 Feb

BRIEF-Apellis Pharmaceuticals Q4 Basic EPS USD -0.29

Reuters
·
28 Feb

Apellis Pharmaceuticals Q4 Product Revenue USD 191.172 Million

THOMSON REUTERS
·
28 Feb

Apellis Pharmaceuticals Q4 Basic EPS USD -0.29

THOMSON REUTERS
·
28 Feb